GO:1904842 response to nitroglycerin: Hemodynamic Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904842 response to nitroglycerin describes any process that changes a cell or organism's state or activity after exposure to nitroglycerin, including movement, secretion, enzyme production and gene expression.
• Nitroglycerin is a nitric oxide donor used clinically as a vasodilator; the response is best documented in the cardiovascular system, where it produces hypotension and reflex tachycardia.
• The response is age-dependent: elderly conscious patients show an accentuated hypotensive response to nitroglycerin compared with younger patients.
• Protein kinase C beta (PRKCB) does not appear to mediate the acute blood pressure response to nitroglycerin, as ruboxistaurin inhibition failed to enhance it.
• In type 1 diabetes, retinal vessels show reduced response to flicker stimulation but preserved response to exogenous nitric oxide, indicating that nitroglycerin responsiveness can be dissociated from endogenous NO signaling.
• Nitroglycerin is widely used as an experimental trigger in headache research, including migraine and cluster headache provocation models.
Description
GO:1904842 response to nitroglycerin is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus. Nitroglycerin (also called nitroglycerine, nitroglycerol, trinitroglycerin or trinitroglycerol) is an organic nitrate that acts as a nitric oxide donor and is used clinically as a vasodilator. The term therefore captures the full spectrum of physiological and cellular reactions triggered by nitroglycerin exposure, from acute hemodynamic changes to longer-term transcriptional responses. The response to nitroglycerin is of broad research interest because it intersects with cardiovascular physiology, autonomic regulation, vascular biology and headache disorders. In conscious elderly patients, nitroglycerin produces an accentuated hypotensive response, illustrating that host factors such as age strongly modify the process. In patients with idiopathic hypertrophic subaortic stenosis, the circulatory response to nitroglycerin and to the Valsalva maneuver has been characterized, showing how the drug unmasks dynamic outflow obstruction. Beyond the clinic, nitroglycerin is a standard experimental tool for probing nitric oxide signaling, vascular reactivity and trigeminal nociceptive pathways. For researchers, GO:1904842 provides a controlled vocabulary to annotate genes, proteins and pathways that mediate nitroglycerin responsiveness. Because the term is defined by the stimulus rather than by a single molecular mechanism, it encompasses vasodilation, reflex neurohumoral activation, enzyme induction and gene expression changes. This makes it a useful anchor for functional genomics, CRISPR screening and translational studies that aim to identify modulators of nitroglycerin response.
response to nitroglycerin At A Glance
| GO ID | GO:1904842 |
|---|---|
| GO term | response to nitroglycerin |
| Ontology | biological_process |
| Synonym | response to nitroglycerine; response to nitroglycerol; response to trinitroglycerin; response to trinitroglycerol |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus. |
| Major function | Mediates cellular and organismal responses to nitroglycerin, a nitric oxide donor and vasodilator, including hemodynamic, neurohumoral and transcriptional changes. |
| Stimulus | Nitroglycerin (organic nitrate, NO donor) |
| Representative phenotypes | Hypotension, reflex tachycardia, headache provocation, altered vascular reactivity |
| Related disease areas | Cardiovascular disease, migraine and cluster headache, diabetes-associated vascular dysfunction |
What Is GO:1904842?
In simple terms, GO:1904842 response to nitroglycerin is the collection of all biological changes that happen in a cell or organism after it encounters nitroglycerin. The official QuickGO definition states that it is any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitroglycerin stimulus. This includes rapid physiological events such as vasodilation and blood pressure reduction, reflex responses such as tachycardia, and slower adaptive changes involving altered gene expression or enzyme activity. The term is a biological process and is not restricted to a single tissue or cell type; it can be applied to vascular smooth muscle, endothelial cells, neurons, or whole-organism responses. Synonyms include response to nitroglycerine, response to nitroglycerol, response to trinitroglycerin and response to trinitroglycerol.
Why Is response to nitroglycerin Important in Cell Biology?
GO:1904842 response to nitroglycerin is important because nitroglycerin is one of the most widely used cardiovascular drugs and a common experimental probe for nitric oxide biology. Understanding the genes and pathways that mediate the response can reveal mechanisms of vasodilator tolerance, inter-individual variability in drug response, and the neurovascular basis of headache. The term also provides a standardized annotation target for functional genomics studies, allowing researchers to compare nitroglycerin-responsive gene sets across cell types and disease models.
• Nitroglycerin is a first-line vasodilator for angina and acute heart failure, so understanding its biological response has direct clinical relevance.
• The hypotensive response to nitroglycerin is accentuated in elderly conscious patients, highlighting age as a key modifier of the process.
• Protein kinase C beta (PRKCB) inhibition does not enhance the acute blood pressure response to nitroglycerin, helping to exclude this pathway as a major mediator.
• In type 1 diabetes, retinal vessel response to flicker is reduced while exogenous nitric oxide response is preserved, showing that nitroglycerin responsiveness can be selectively altered in disease.
• Nitroglycerin is used experimentally to provoke migraine and cluster headache attacks, linking the response to trigeminovascular activation.
• The term supports annotation of genes involved in nitric oxide signaling, cGMP metabolism, vascular smooth muscle contraction and autonomic reflexes.
• It provides a framework for CRISPR screens aimed at identifying modifiers of nitroglycerin sensitivity.
• It is relevant to pharmacogenomics, as inter-individual differences in nitroglycerin response may reflect genetic variation in NO-cGMP pathway components.
• It connects to lateral epicondylalgia and tendon research, where nitroglycerin has been explored for its effects on tendon healing and pain.
• It overlaps with autonomic testing such as head-up tilt table testing, which evaluates reflex responses related to nitroglycerin-induced hypotension.
What Happens During response to nitroglycerin?
Nitric oxide release and immediate vascular signaling
In simple terms: Nitroglycerin breaks down to release nitric oxide, which tells blood vessels to relax.
Nitroglycerin is an organic nitrate that acts as a nitric oxide (NO) donor. After administration, it is metabolized to release NO or related reactive species, which activate soluble guanylate cyclase and increase cyclic GMP in vascular smooth muscle cells. This leads to smooth muscle relaxation and vasodilation. The circulatory response to nitroglycerin has been documented in patients with idiopathic hypertrophic subaortic stenosis, where the drug reduces preload and can alter dynamic outflow obstruction. The acute blood pressure response is a defining feature of GO:1904842.
Hemodynamic changes and reflex neurohumoral activation
In simple terms: Blood pressure drops, and the body reflexively speeds up the heart and constricts some vessels.
The primary hemodynamic consequence of nitroglycerin is venodilation and arterial dilation, which reduce preload and afterload. In conscious elderly patients, this hypotensive response is accentuated compared with younger individuals, indicating age-related differences in baroreflex compensation or vascular sensitivity. The fall in blood pressure triggers reflex sympathetic activation, leading to tachycardia and increased peripheral resistance. These reflex responses are part of the organism-level response to nitroglycerin and are relevant to autonomic testing such as head-up tilt table testing.
Cellular and enzymatic responses
In simple terms: Cells change their enzyme activity and signaling in response to nitroglycerin.
Beyond vasodilation, nitroglycerin exposure alters enzyme production and activity in various cell types. The definition of GO:1904842 explicitly includes changes in enzyme production and gene expression. Studies on protein kinase C beta (PRKCB) show that inhibiting this kinase with ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin, suggesting that PRKCB is not a limiting factor in this acute response. This negative result helps define the boundaries of the process and guides further investigation of alternative signaling mediators.
Tissue-specific and disease-modified responses
In simple terms: Different tissues and diseases can change how the body reacts to nitroglycerin.
The response to nitroglycerin is not uniform across tissues or disease states. In type 1 diabetes, retinal vessels show reduced response to flicker stimulation but preserved response to exogenous nitric oxide, indicating that neurovascular coupling is impaired while direct NO responsiveness remains intact. This dissociation is important for interpreting nitroglycerin response data in metabolic disease. In headache research, nitroglycerin is used to provoke migraine and cluster headache attacks, linking the response to trigeminovascular activation and neurogenic inflammation. In tendon research, nitroglycerin has been explored for its effects on lateral epicondylalgia, a midlife tendon disorder.
Transcriptional and adaptive responses
In simple terms: Over time, nitroglycerin can change which genes are turned on or off.
The GO definition includes gene expression changes as part of the response. Repeated or sustained nitroglycerin exposure can lead to adaptive changes such as tolerance, which involves altered gene expression, oxidative stress and neurohumoral adaptation. Although specific transcriptional signatures are not detailed in the verified citations, the term explicitly encompasses these slower adaptive processes. Researchers can use RNA-seq and other transcriptomic methods to identify genes whose expression changes after nitroglycerin treatment, thereby annotating new participants in GO:1904842.
Key Genes Involved in GO:1904842 response to nitroglycerin
The following genes and proteins have been implicated in the response to nitroglycerin or in related nitric oxide-cGMP signaling, based on the verified literature and established pathway knowledge.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKCB | Protein kinase C beta; signaling mediator | Inhibition with ruboxistaurin does not enhance acute blood pressure response to nitroglycerin |
| GUCY1A1 | Soluble guanylate cyclase subunit alpha-1; NO receptor | Mediates cGMP production in response to nitric oxide released from nitroglycerin |
| GUCY1B1 | Soluble guanylate cyclase subunit beta-1; NO receptor | Partners with GUCY1A1 to form the NO-sensitive guanylate cyclase |
| NOS3 | Endothelial nitric oxide synthase; produces NO | Modulates baseline vascular tone and may influence nitroglycerin responsiveness |
| ALDH2 | Aldehyde dehydrogenase 2; bioactivation of nitroglycerin | Mitochondrial ALDH2 is a key enzyme for nitroglycerin bioactivation and tolerance |
| CYP2C9 | Cytochrome P450 family 2 subfamily C member 9 | May contribute to nitroglycerin metabolism and inter-individual variability |
| CYP3A4 | Cytochrome P450 family 3 subfamily A member 4 | Involved in oxidative metabolism of nitroglycerin |
| GNAI1 | G protein subunit alpha i1; inhibitory G protein | May modulate downstream signaling in vascular smooth muscle |
| ADRB1 | Beta-1 adrenergic receptor; mediates tachycardia | Reflex tachycardia after nitroglycerin-induced hypotension involves beta-adrenergic signaling |
| ADRB2 | Beta-2 adrenergic receptor; vascular relaxation | Contributes to vasodilation and smooth muscle relaxation |
| CALM1 | Calmodulin 1; calcium sensor | Regulates nitric oxide synthase activity and smooth muscle contraction |
| PRKG1 | cGMP-dependent protein kinase 1; mediates vasodilation | Key effector of cGMP signaling downstream of nitroglycerin |
| TRPV1 | Transient receptor potential vanilloid 1; nociceptor | Implicated in nitroglycerin-induced headache and trigeminal activation |
| CGRP | Calcitonin gene-related peptide; vasodilatory neuropeptide | Released during nitroglycerin-induced migraine attacks |
| ACE | Angiotensin-converting enzyme; blood pressure regulation | Modulates vascular tone and may influence hemodynamic response to nitroglycerin |
| EDN1 | Endothelin 1; vasoconstrictor | Counter-regulatory peptide that may affect net response to nitroglycerin |
| NPPA | Natriuretic peptide A; vasodilator | May interact with cGMP pathways shared with nitroglycerin signaling |
How Is response to nitroglycerin Regulated?
The response to nitroglycerin is regulated at multiple levels. Acutely, the availability of nitric oxide from nitroglycerin bioactivation determines the magnitude of guanylate cyclase stimulation and cGMP production. Enzymes such as ALDH2 and cytochrome P450 isoforms influence bioactivation and tolerance. Protein kinase C beta (PRKCB) has been tested as a regulator, but its inhibition does not enhance the acute blood pressure response to nitroglycerin, suggesting that PRKCB is not a primary limiting regulator in this context. Reflex autonomic pathways, including baroreceptor-mediated sympathetic activation, modulate heart rate and vascular tone, and these pathways may be altered by age, as shown by the accentuated hypotensive response in elderly conscious patients. In disease states such as type 1 diabetes, neurovascular coupling can be impaired while direct NO responsiveness is preserved, indicating that regulation of the response is tissue- and context-dependent. Head-up tilt table testing provides a framework for evaluating autonomic regulation relevant to nitroglycerin-induced hemodynamic changes.
response to nitroglycerin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKCB | Hypertension and vascular tone regulation | PRKCB knockout or point-mutation cell model to test nitroglycerin-induced cGMP changes |
| ALDH2 | Nitroglycerin bioactivation and tolerance | ALDH2 knockout endothelial or smooth muscle cells for nitroglycerin response assays |
| GUCY1A1/GUCY1B1 | NO-cGMP signaling in cardiovascular disease | Knock-in of patient variants to assess cGMP production after nitroglycerin |
| TRPV1 | Migraine and trigeminal nociception | TRPV1 knockout sensory neurons for nitroglycerin-induced CGRP release |
| CGRP | Migraine and cluster headache | CGRP overexpression or knockout models for nitroglycerin provocation studies |
Cardiovascular disease and hemodynamic disorders
Nitroglycerin is used clinically to reduce cardiac preload and afterload in angina and heart failure. The circulatory response to nitroglycerin has been characterized in patients with idiopathic hypertrophic subaortic stenosis, where the drug can provoke dynamic outflow obstruction and hypotension. In elderly conscious patients, the hypotensive response is accentuated, which has implications for safe dosing in older adults. These findings link GO:1904842 to cardiovascular risk assessment and perioperative management.
Migraine and cluster headache
Nitroglycerin is a well-established trigger for migraine and cluster headache attacks in experimental settings. The common link between migraine and cluster headache involves trigeminovascular activation and neuropeptide release, including CGRP. A case report describes chronic migraine with apparent loss of response to onabotulinum toxin type A due to local nitroglycerin treatment for an anal fissure, illustrating how exogenous nitroglycerin can interact with headache management. These observations make GO:1904842 relevant to headache research and to understanding NO-mediated nociception.
Diabetes-associated vascular dysfunction
In type 1 diabetes, retinal vessels show reduced response to flicker stimulation but not to exogenous nitric oxide, indicating that neurovascular coupling is impaired while direct NO responsiveness is preserved. This dissociation suggests that nitroglycerin response can be used to probe distinct aspects of vascular function in diabetes. It also implies that therapies targeting NO signaling may retain efficacy even when endogenous neurovascular control is compromised.
Tendon disorders and musculoskeletal pain
Lateral epicondylalgia, a common tendon disorder, has been studied in the context of nitroglycerin treatment for its potential effects on tendon healing and pain. Although the evidence base is limited, this connection broadens the relevance of GO:1904842 beyond the cardiovascular system and highlights the need for further research on nitroglycerin-responsive pathways in musculoskeletal tissues.
From response to nitroglycerin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH2 alter nitroglycerin bioactivation? | ALDH2 knockout cell line (endothelial or smooth muscle) |
| Does a specific GUCY1A1 variant change cGMP response to nitroglycerin? | Point-mutation knock-in of the variant in a vascular cell line |
| Can a tagged NO sensor report real-time nitroglycerin response? | Tagged knock-in of a fluorescent cGMP reporter |
| Does overexpression of PRKG1 enhance nitroglycerin-induced vasodilation? | PRKG1 overexpression stable cell line |
| Which genes modify nitroglycerin sensitivity in a genome-wide screen? | CRISPR knockout library screening in a vascular or neuronal cell model |
| Does TRPV1 mediate nitroglycerin-induced CGRP release? | TRPV1 knockout or overexpression in sensory neuron cultures |
How to Study the response to nitroglycerin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify nitroglycerin-responsive genes and pathways |
| cGMP immunoassay | Intracellular cGMP levels | Quantify NO-guanylate cyclase activation after nitroglycerin |
| Isolated vessel myography | Vasodilation and contractility | Assess vascular response to nitroglycerin ex vivo |
| Blood pressure telemetry | Hemodynamic response in vivo | Measure hypotensive effect and reflex tachycardia |
| Retinal vessel analysis | Neurovascular coupling and NO response | Evaluate nitroglycerin response in diabetic models |
| Head-up tilt table testing | Autonomic reflex function | Assess baroreflex modulation of nitroglycerin response |
| CRISPR knockout screen | Gene requirement for nitroglycerin sensitivity | Discover novel modulators of GO:1904842 |
| Proteomics | Protein abundance and post-translational modifications | Identify signaling changes after nitroglycerin exposure |
Transcriptomic profiling of nitroglycerin response
RNA-seq can be used to identify genes whose expression changes after nitroglycerin exposure in cultured cells or animal models. This approach helps annotate new participants in GO:1904842 and can reveal tissue-specific transcriptional signatures. Comparing treated and untreated samples across genotypes (e.g., knockout versus wild-type) can establish causality for candidate genes.
Functional assays for vascular reactivity
Isolated vessel myography, blood pressure telemetry and retinal vessel analysis can measure the physiological response to nitroglycerin. In type 1 diabetes, retinal vessel response to flicker and exogenous nitric oxide has been assessed, providing a template for dissecting neurovascular versus direct NO effects. Head-up tilt table testing can evaluate autonomic reflexes related to nitroglycerin-induced hypotension.
Biochemical measurement of NO-cGMP signaling
cGMP levels can be quantified by immunoassay or mass spectrometry after nitroglycerin treatment. Enzyme activity assays for ALDH2, guanylate cyclase and protein kinases can determine which pathways are engaged. Testing PRKCB inhibition with ruboxistaurin in such assays can confirm whether this kinase modulates the response.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens can identify genes that modify cellular sensitivity to nitroglycerin. Hits can be prioritized using pathway enrichment, protein-protein interaction networks and transcriptomic data. Bioinformatics integration of screen results with known NO-cGMP pathway components helps build mechanistic models of GO:1904842.
How CRISPR Can Be Used to Study GO:1904842 response to nitroglycerin
Knockout
CRISPR knockout of candidate genes such as ALDH2, GUCY1A1, GUCY1B1 or PRKCB can test their requirement for nitroglycerin-induced responses. For example, knocking out ALDH2 in endothelial cells would help determine whether nitroglycerin bioactivation is impaired. Knockout of PRKCB can validate the negative findings from pharmacological inhibition studies. These models are essential for establishing causal roles in GO:1904842.
Point Mutation
Point-mutation knock-in can model human variants in genes such as GUCY1A1, GUCY1B1 or ALDH2 that may alter nitroglycerin sensitivity. By introducing a single nucleotide change, researchers can assess whether a specific variant changes cGMP production, vasodilation or gene expression after nitroglycerin treatment. This approach is particularly useful for pharmacogenomic studies of inter-individual variability in drug response.
Knock-in
Knock-in of reporter genes, such as a fluorescent cGMP biosensor or a tagged signaling protein, allows real-time monitoring of nitroglycerin response in living cells. Tagged knock-in of GUCY1A1 or PRKG1 can reveal localization and dynamics of these proteins after stimulation. These models provide spatial and temporal resolution that bulk assays cannot achieve.
Overexpression
Overexpression of genes such as PRKG1, NOS3 or CGRP can test whether increased levels enhance or dampen the response to nitroglycerin. For example, overexpressing PRKG1 in vascular smooth muscle cells may amplify cGMP-dependent vasodilation. Overexpression models are also useful for studying gain-of-function mechanisms and for validating drug targets within the GO:1904842 pathway.
How EDITGENE Supports response to nitroglycerin Research
Researchers studying response to nitroglycerin-related genes often need to determine whether a candidate gene is causally involved in the response or merely correlated with it. CRISPR-based models provide a rigorous way to test causality by introducing precise genetic changes in relevant cell types. EDITGENE offers a comprehensive suite of services to support such studies, from knockout and point-mutation models to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for response to nitroglycerin research.
Frequently Asked Questions About response to nitroglycerin
What is GO:1904842 response to nitroglycerin?
GO:1904842 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of a nitroglycerin stimulus, including movement, secretion, enzyme production and gene expression.
What genes are involved in response to nitroglycerin?
Genes implicated in the response include ALDH2, GUCY1A1, GUCY1B1, PRKG1, NOS3, PRKCB, TRPV1 and CGRP, based on their roles in nitric oxide signaling, cGMP production and neurovascular activation.
How does nitroglycerin cause vasodilation?
Nitroglycerin releases nitric oxide, which activates soluble guanylate cyclase, increases cGMP and relaxes vascular smooth muscle, leading to vasodilation and reduced blood pressure.
Why is the hypotensive response to nitroglycerin accentuated in the elderly?
Elderly conscious patients have an accentuated hypotensive response to nitroglycerin, possibly due to age-related changes in baroreflex function or vascular sensitivity.
Does protein kinase C beta regulate the response to nitroglycerin?
Inhibition of PKC beta with ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin, suggesting PRKCB is not a primary regulator of this response.
Is nitroglycerin used to trigger migraines in research?
Yes, nitroglycerin is used experimentally to provoke migraine and cluster headache attacks, linking the response to trigeminovascular activation and CGRP release.
How is nitroglycerin response studied in diabetes?
In type 1 diabetes, retinal vessel response to flicker is reduced while exogenous nitric oxide response is preserved, allowing researchers to dissect neurovascular versus direct NO effects.
What CRISPR models are useful for studying response to nitroglycerin?
Knockout, point-mutation, knock-in and overexpression models of genes such as ALDH2, GUCY1A1, PRKG1 and TRPV1 can be used to test causality and mechanism in the nitroglycerin response pathway.
Can nitroglycerin treatment affect headache management?
A case report describes chronic migraine with apparent loss of response to onabotulinum toxin type A due to local nitroglycerin treatment for an anal fissure, highlighting potential interactions.
What methods measure the response to nitroglycerin?
Methods include RNA-seq, cGMP assays, isolated vessel myography, blood pressure telemetry, retinal vessel analysis, head-up tilt table testing and CRISPR screens.
Conclusion
GO:1904842 response to nitroglycerin captures a clinically and biologically important process that spans vascular biology, autonomic regulation and neurovascular signaling. The verified literature documents key features such as the accentuated hypotensive response in the elderly, the lack of PRKCB involvement in acute blood pressure changes, preserved exogenous NO responsiveness in diabetic retinopathy, and the use of nitroglycerin as a headache trigger. These findings provide a foundation for functional genomics studies aimed at identifying the full set of genes and pathways that mediate the response. CRISPR-based models offer a powerful approach to dissect the causal roles of candidate genes in GO:1904842. By combining knockout, point-mutation, knock-in and overexpression strategies with transcriptomic, biochemical and physiological assays, researchers can build a mechanistic understanding of nitroglycerin responsiveness. EDITGENE provides the tools and services to support these efforts, from custom cell model generation to library screening and bioinformatics analysis.
References
- 1. Pérez-Pereda S et al.. 2020. Chronic Migraine With Apparent Loss of Response to Onabotulinum Toxin Type A Due to Local Nitroglycerin Treatment for an Anal Fissure: A Case Report.. Headache 60(10):2570-2572 PMID: 32491189
- 2. Cahalan MK et al.. 1992. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin.. Anesthesiology 77(4):646-55 PMID: 1416161
- 3. BRAUNWALD E et al.. 1964. THE CIRCULATORY RESPONSE OF PATIENTS WITH IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS TO NITROGLYCERIN AND TO THE VALSALVA MANEUVER.. Circulation 29:422-31 PMID: 14128830
- 4. Benson C et al.. 2007. Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.. Clin Pharmacol Ther 82(2):181-6 PMID: 17443133
- 5. Pemp B et al.. 2009. Reduced retinal vessel response to flicker stimulation but not to exogenous nitric oxide in type 1 diabetes.. Invest Ophthalmol Vis Sci 50(9):4029-32 PMID: 19369238
- 6. Vollesen AL et al.. 2018. Migraine and cluster headache - the common link.. J Headache Pain 19(1):89 PMID: 30242519
- 7. Luk JK et al.. 2014. Lateral epicondylalgia: midlife crisis of a tendon.. Hong Kong Med J 20(2):145-51 PMID: 24584568
- 8. Tan MP et al.. 2009. Head-up Tilt Table Testing: a state-of-the-art review.. Minerva Med 100(4):329-38 PMID: 19749686
